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REVIEW
Abstract: The prevalence of type 2 diabetes is increasing among older adults as is their
diabetes-related mortality rate. Studies suggest that tighter glucose control reduces
complications in elderly patients. However, too low a glycosylated hemoglobin (HbA1c) value
is associated with increased hypoglycemia. Moreover, the appropriateness of most clinical
trial data and standards of care related to diabetes management in elderly patients is questionable
given their heterogeneity. Having guidelines to safely achieve glycemic control in elderly
patients is crucial. One of the biggest challenges in achieving tighter control is predicting
when peak insulin action will occur. The clinician’s options have increased with new insulin
analogs that physiologically match the insulin peaks of the normal glycemic state, enabling
patients to achieve the tighter diabetes control in a potentially safer way. We discuss the
function of insulin in managing diabetes and how the new insulin analogs modify that state.
We offer some practical considerations for individualizing treatment for elderly patients with
diabetes, including how to incorporate these agents into current regimens using several methods
to help match carbohydrate intake with insulin requirements. Summarizing guidelines that
focus on elderly patients hopefully will help reduce crises and complications in this growing
segment of the population.
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Introduction
Diabetes mellitus is a major health concern that affects over 150 million adults or
5.4% of the population worldwide; this number will double in the next 25 years
(King et al 1998). More specifically, in developed countries defined as Europe, North
America, Australia, New Zealand, and Japan, the number of people with diabetes is
expected to increase 42% over the next twenty years and in all other developing
countries the increase is expected to be 170%. In the US between 1980 and 2003, the
number of people with diabetes more than doubled, rising from 5.8 million to 13.8
million (CDC 2005). In 2003, more than 1.3 million adults were diagnosed with
diabetes, representing a 52% increase over the number of new cases, 878000, in
1997 (CDC 2005).
These trends greatly affect the elderly and near elderly as most people with diabetes
in the developed world are over 65 years of age, while that of developing countries
are 45 to 64 years old. Type 2 diabetes is diagnosed in 10.6% of people over the age
of 74 years in the US (NIH 1975). A study reports that one-third of elderly Europeans
between age 70 and 75 years have diabetes or impaired fasting glucose (Teuscher et
al 1999). The elderly diabetes-related mortality rate is particularly high with 62.3 per
1000 person-years in women and 81.8 per 1000 person-years in men (Bertonia et al
2002).
The American Diabetes Association (ADA) changed their target hemoglobin (A1c)
level to 7% in recent years based on large, randomized, interventional trials showing
that tight glycemic control significantly reduces the risk of developing diabetes
complications and, ultimately, the cost of diabetes care (ADA 2005). Studies suggest
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that tighter glucose control reduces the chance and severity
of stroke, blindness, nephropathy, cardiovascular disease,
infections, and even cognitive dysfunction in the elderly
(Samos and Roos 1998; CHF/AGSP 2003). It is mindful to
consider that a 65 year old now has an 18-year life
expectancy that provides time to incur long-term
complications (Hogikyan and Halter 1997).
However, too low an A1c value is associated with
increased hypoglycemia as a Swedish study noted when an
elderly community averaged a glycosylated hemoglobin
(HbA1c) of 5.9 (Lofgren et al 2004). Of utmost concern in
the elderly population is the concern for increased falls with
episodes of hypoglycemia creating a cascade of other
medical sequela which the patient, family, and provider are
anxious to avoid (CHF/AGSP 2003). Thus, hypoglycemia
in older adults is a particular challenge for diabetes
management because there are increased and unique risk
factors (Nettles 2005). Higher risk is associated with the
following age-related changes: decreased renal function,
slowed hormonal regulation and counter-regulation,
suboptimal hydration, and slowed intestinal functioning
(absorption). The increased likelihood of older adults being
on multiple medications and exhibiting inadequate and/or
erratic nutritional intake introduces factors that put them at
higher risk for hypoglycemia. At the same time, it is also
important to note that older adults are at increased risk for
having hyper and hypoglycemic symptoms misattributed to
other factors such as other comorbid conditions, side effects
from medications, or the aging process itself.
One of the biggest struggles for clinicians in achieving
tight control while preventing hypoglycemia in their elderly
patients is to predict when peak insulin action will occur.
This depends not only on the patient’s carbohydrate intake
and absorption, but on their activity level as well.
Miscalculating an elderly patient’s insulin requirements may
lead to a sharp, severe lowering of blood glucose,
necessitating emergency treatment (Watts and Ober 2005).
The clinicians’ options for safe insulin regimens in the
geriatric population have expanded greatly in the last 10
years. It now includes several insulin analogs: these are
synthesized drugs that have a modified pharmacokinetic
profile by altering the amino acid sequence of natural insulin
(Engel et al 2004a, 2004b). These analogs show great
promise to help patients lower their blood glucose to levels
because their pharmacokinetics nearly mimic the physiology
of the nondiabetic state (Mudaliar et al 1999; Lepore et al
2000; Bode 2004). These new insulin analogs
physiologically match the insulin peaks of the normal
glycemic state, enabling patients to achieve the tighter
diabetes control in potentially a safer way.
Glycemic control does not happen in a vacuum and this
is particularly true for older adults. The heterogeneity in
clinical and functional status among elderly patients has
important ramifications for the management of diabetes.
Elderly patients with diabetes are disproportionately affected
by other health conditions and adverse outcomes such as
cognitive impairment, limitations in functional status,
depressive symptoms, heart disease, and stroke (Blaum et
al 2003; CHF/AGSP 2003; ADA 2005; Nettles 2005). The
potential costs in terms of morbidity are particularly salient
in light of the consideration that a recent study found that
the majority of their sample of older patients with type 2
diabetes indicated that a primary health goal was maintaining
independence in daily living (Huang et al 2005). The
clinician must weigh many factors as the risks and benefits
of tight glycemic control in elderly patients are evaluated in
the context of treatment strategies and priorities.
Thus, while some have endorsed lowering the goal of
HbA1c levels to less than or equal to 7.0%, the importance
of tailoring or individualizing the target level is often
acknowledged when applying this recommendation to an
elderly population (eg, CHF/AGSP 2003). At the same time
this introduces controversy and a lack of consensus about
managing diabetes in elderly patients. This is due in part to
the complexity and heterogeneity of their clinical and
functional status and currently having no studies that address
the longer-term benefits and risks associated with tight
glycemic control in older adults (ADA 2005). Insulin analogs
are available now to help the clinician manage diabetes in
such a complex and heterogeneous population but it is
critical to understand the risk and benefits of these analogs.
We will discuss the function of insulin in managing
diabetes and consider how the newer insulin analogs assist
with the overall goal of providing optimum diabetes disease
management with a focus on the special concerns when
treating elderly patients. Specifically, we will review what
factors clinicians should consider when revising a patient’s
insulin regimen to include these analogs and suggest several
methods, including correction factors, by which appropriate
dosages may be deduced. The insulin treatment guidelines
summarized and presented with elderly patients in mind
hopefully will help to reduce crises and complications in
this growing segment of the population and provide safe
options for individualizing treatment.Clinical Interventions in Aging 2006:1(2) 109
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Insulin’s pathophysiology and
management of diabetes
The pancreas produces a constant, or basal, production and
circulation of insulin, which regulates the output of hepatic
glucose (maintaining blood levels above 60mg/dL) and
modulates muscle and other tissue uptake. Additionally, a
physiologic bolus of insulin is secreted at mealtimes in
proportion with the carbohydrate intake. This helps the body
utilize this energy source for metabolism.
Glucose lowering agents are often necessary to help
patients with diabetes achieve the tight glucose control that
their pancreas cannot achieve. Patients with type 1 diabetes
require insulin injections because of a complete lack of
endogenous insulin; however patients with type 2 diabetes
may achieve glycemic control through oral medications. A
common scenario occurs when oral therapy no longer
maintains blood glucose within generally accepted targets
and injected insulin may then need to be added to the
regimen. However, oral glucose lowering agents should not
necessarily be discontinued at this time. Indeed, these can
work synergistically with insulin to make the regimen more
effective (Wright et al 2002).
There are no clinical guidelines when to intensify
medical therapy in the elderly. Each patient must be treated
individually. However, if the fasting plasma glucose is
roughly 200mg/dL despite maximal oral glucose lowering
agents, then prandial values exceed this number with the
resultant potential for significant hyperglycemia, and an
injectable agent should be considered (Saudek and Golden
1999).
Historical insulin effects
The regular human insulins were the only formulations
available during the past decades to provide patients with
the necessary preprandial bolus doses. Regular insulin’s
onset of action begins in 30 minutes to one hour (Table 1)
(Dailey 2004; Engel et al 2004b; Drug Guide 2005) and
reaches peak serum concentrations corresponding to peak
action in about two to four hours (Dailey 2004). This delayed
onset means the patient must carefully plan mealtimes to
avoid hypoglycemia and doesn’t allow for too much variance
such as skipping a meal or overeating.
Historically, basal insulin was provided through various
regimens using either intermediate-acting neutral protamine
Hagedorn (NPH) insulin, insulin lente, or long-acting
ultralente insulin. NPH insulin has the earliest onset of action
beginning in two hours (Engel et al 2004b). Peak serum
concentrations are variable with five to seven hours for NPH
insulin, four to eight hours for insulin lente, or unpredictable
for ultralente (Dailey 2004). The latter two insulins are
currently being phased out in formularies in the US (Fleming
2005).
The rapid-acting insulin analogs, insulin lispro and
insulin aspart, as well as the long-acting analog, insulin
glargine, have added a new facet to diabetes therapy with
improved onset and peak concentration times. Due to their
smooth action and predictability, these insulins offer an ideal
match with the elderly population to avoid hypoglycemia.
New insulin analogs
Three rapid acting insulin analogs have been introduced in
the last nine years. The insulins lispro and aspart were
brought to the US market in 1996 and 1999, respectively,
and in April 2004, the US Food and Drug Administration
(FDA) approved a third rapid-acting analog, Insulin glulisine
(Thompson 2004). The insulins lispro and aspart achieve
peak concentration within 90 minutes and have a duration
of action of approximately three to five hours (Bode 2004),
while glulisine’s peak concentration is within an hour, and
its duration of action is roughly two hours (Drug Guide
2005). All three of these rapid-acting analogs have an onset
of action within 15 minutes. This rapid onset of action means
that the patient can now pair the dose of insulin injected to
the amount of carbohydrate consumed. Timing slightly
Table 1 Pharmacodynamics of human insulin and insulin
analogs1
Insulin type Time to onset Time to Duration of
of action (h)  peak action (h) action (h)
Human insulin
Rapid-acting
• Regular insulin 0.5–1 2–4 6–8
Intermediate-acting
• NPH insulin 2–4 5–7 14–24
• Insulin lente 3–4 4–8 16–20
Long-acting
• Ultralente insulin 6–10 Unpredictable 20–24
Insulin analogs
Rapid-acting
• Insulin lispro 0.25 1.5 3–5
• Insulin aspart 0.25 1.5 3–5
• Insulin glulisine 0.25 1 2
Long-acting
• Insulin glargine 2–4 Peakless 20–24
1Wide variations occur among patients. (Bode 2004; Engel et al 2004; Watts and
Kern 2004; Watts and Ober 2005).
Abbreviations: NPH, neutral protamine Hagedorn.Clinical Interventions in Aging 2006:1(2) 110
Ober et al
varies among the insulins: insulin lispro can be taken up to
15 minutes before a meal or immediately after a meal, insulin
aspart immediately or within 10 minutes of starting a meal,
and insulin glulisine up to 15 minutes prior to or 20 minutes
of starting a meal (Drug Guide 2005). Elderly patients with
renal insufficiency may benefit from the quick action of
lispro and experience less hypoglycemic episodes (Velussi
2002).
Hypoglycemia is a dangerous complication of all types
of insulin and patients should be cautioned not to administer
any of the rapid-acting analogs at bedtime. These analogs
are solely to be used for mealtime insulin coverage and, if
administered at bedtime, can cause glucose levels to drop
severely during sleep. For those patients who just can’t seem
to resist constant evening snacking on carbohydrates, regular
insulin, which has a longer time to peak concentration and
a longer duration of action, may provide a longer duration
of blood glucose lowering (Watts and Ober 2005). As such,
it is critical to understand each elderly patient’s meal and
snacking preferences and habits.
Elderly patients and their families need to understand
the time course of these new insulins. We have seen patients
who believe they can inject a rapid-acting analog at home
and then go to a restaurant and order a meal, a practice
similar to bedtime administration, which causes potentially
life-threatening episodes of hypoglycemia. Patient and
family education cannot be over-emphasized as in one study
nearly 32% of elderly patients receiving insulin had no
knowledge regarding hypoglycemia (Thomson et al 1991).
Insulin glargine
Initially introduced in 2001, insulin glargine has been touted
as the first major advancement in the treatment of type 1
and type 2 diabetes in over 50 years (Home and Ashwell
2002). This analog delivers a basal insulin delivery that has
no significant peak, and can be administered at nearly any
time of the day, be it morning, noon, or evening, provided
that the patient consistently administers it at the same time
each day.
The time to onset of action is two to four hours and total
duration of action is about 20 to 24 hours (Bode 2004). There
is a lower incidence of associated symptomatic
hypoglycemia and nocturnal hypoglycemia in type 1 and
type 2 diabetes when compared with NPH insulin (Ratner
et al 2000; Yki-Jarvinen et al 2000; Rosenstock et al 2001).
However, insulin glargine cannot be mixed with any other
insulins due to its acidic pH.
The glargine package insert suggests reducing the dosage
by 20% when converting from other basal insulins to insulin
glargine – especially if the patient has type 1 diabetes. The
peakless insulin glargine is likely to provide tighter blood
glucose control than the older basal insulins, which produce
peak concentration levels requiring patients to self-treat
episodes of hypoglycemia with carbohydrate snacks and
ultimately administering additional insulin to compensate
for the resulting hyperglycemia (Janka et al 2005). Such a
risky adjustment cycle is of particular concern among elderly
patients and emphasizes the importance of education to
achieve tighter and safer glucose control.
Insulin therapy in patients with type 1 diabetes usually
is initiated at a total daily dosage (TDD) of 0.3IU/kg to
0.8IU/kg per day (APA 2001). In patients with moderate
type 2 diabetes (defined as a fasting blood glucose between
140–250mg/dL), the patient’s TDD of insulin usually ranges
from 0.3IU/kg to 0.6IU/kg (APA 2001; ADA 2002).
After the correct TDD of insulin is determined, patients
with type 1 diabetes may take half that amount in the form
of basal insulin and half in the form of rapid-acting insulin,
the latter is equally divided between three mealtime bolus
doses in basic proportion to the amount of carbohydrates
consumed.
A strategy in patients with type 2 diabetes is to directly
switch from NPH insulin-to-insulin glargine, using glargine
at the same dosage as was used for NPH. The caveat is that
the patient has not experienced any recent episodes of
hypoglycemia.
It is important to monitor both fasting and preprandial
blood glucose levels in order to assess therapeutic efficacy
by comparing them with the American Diabetics Association
(ADA)’s ideal levels, which are 90–130mg/dl (ADA 2005).
Such comparisons can be used to modify therapy (Table 2)
(Watts and Kern 2004) and while of general application the
ADA levels are useful guidelines for elderly patients and
their families.
Table 2 Blood glucose levels indicating excessive circulating
insulin1
Blood glucose levels (mg/dL)
Fasting Pre-lunch Pre-dinner Bedtime
78 60 55 89
111 70 65 109
65 55 68 106
1Patient presenting with such blood glucose readings would be advised to reduce
basal insulin by 10% to 20% and to monitor blood glucose levels closely for
three to four days afterward to determine whether the change has been
effective (Watts and Kern 2004; Watts and Ober 2005).Clinical Interventions in Aging 2006:1(2) 111
Insulin use in elderly patients
Calculating mealtime
carbohydrates
The best method to calculate mealtime insulin is to directly
match the amount of insulin to the expected amount of
carbohydrates to be consumed. This requires some
sophistication as well as a genuine effort made by the patient.
Patients with type 1 diabetes, generally start with dosing
1IU preprandial, rapid-acting insulin for every serving (15g)
of carbohydrate consumed. For patients with type 2 diabetes,
the optimal dose of rapid-acting insulin widely varies due
to insulin resistance.
Such factors in these patients that contribute to the difficulty
of making a standardized calculation include the duration and
progression of the diabetes, the patient’s body mass index,
and genetic factors. However, several methods are available
for roughly estimating the approximate coverage required
(Table 3) (Watts and Ober 2005). Having several methods
permits finding a method that best matches the individual
preferences of and differences among elderly patients.
Method 1: The 500 rule
Patients with good glycemic control, as evidenced by A1c
levels of 7.0% or lower, can determine their insulin-to-
carbohydrate ratio by dividing 500 by their TDD of insulin
(basal + bolus in IU) (Walsh and Roberts 2000). This
approximates the number of carbohydrate grams that 1IU
insulin covers. Extremely insulin-resistant patients may use
a TDD of 100IU insulin; the insulin-to-carbohydrate ratio
would be 1:5, meaning that 1IU insulin can be expected to
provide coverage for 5g carbohydrate (500÷100=5), or
about one third of a piece of bread. A patient with a TDD of
only 20 IU insulin would divide 500 by 20 and arrive at an
insulin-to-carbohydrate ratio of 1:25. For this patient, 1IU
insulin provides coverage for 25g carbohydrate.
Method 2: The conventional formula
A second common method to determine the amount of rapid-
acting insulin needed for preprandial coverage is to use the
convention 1IU per 15g carbohydrate consumed. For
example, if a patient’s planned meal contains approximately
60g carbohydrates, then 4IU rapid-acting insulin (60g ÷
15g=4IU) is required to provide coverage for the meal.
Clinicians must note that this method requires checking both
preprandial and two-hour postprandial glucose levels to
verify accuracy of dosing. If preprandial blood glucose
values are within target range and postprandial levels are
elevated no more than 40mg/dL above preprandial levels,
then the provided bolus dose is sufficient. If postprandial
levels are lower than the preprandial levels, then the
scheduled dose was excessive and hypoglycemia could
ensue.
Method 3: Using body weight
A third formula for calculating the insulin-to-carbohydrate
ratio often is recommended for patients with type 1 diabetes:
[2.8 x (body weight in lbs)] ÷ TDD of insulin (in IU) (Bode
2004). In following this formula, a patient weighing 200lbs
whose TTD of insulin was 50IU, would take 1IU
preprandial insulin for every 11g carbohydrate consumed
([2.8 x 200 lbs]÷50 IU=11.2).
Table 3 Summary chart for methods of calculating insulin and caveats for older patients
Method Approach Caveats
Method 1: 500 rule 500
TDD of insulin (basal + bolus in IU)
Method 2: Conventional formula 1IU per 15g carbohydrate If postprandial levels are lower than
consumed  preprandial levels, hypoglycemia may result
Method 3: Using body weight [2.8 x (body weight in lbs)] Recommended for type 1
TDD of insulin (in IU)
Method 4: No-count approach Small preprandial dose: 2–4 IU* 1. *Factor in weight, type of diabetes
and typical meal
2. Check pre and post-prandial levels regularly
3. Correction factor helpful
CF 1700/TDD(in IU) Patients must not use this at bedtime
Abbreviations: CF, correction factor; TDD, total daily dosage of insulin in IU.Clinical Interventions in Aging 2006:1(2) 112
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Method 4: The no-count approach
For patients unable or unwilling to learn carbohydrate
counting, a small dose (2–4IU, depending on weight, type
of diabetes, and typical meals) of preprandial insulin can be
prescribed. Advise these patients to check preprandial and
2-hr postprandial glucose levels regularly to determine the
accuracy of the dosing. In addition, a correction factor may
also benefit these patients.
Correction factors
There will be occasions, due to stress or overeating, when
blood glucose levels will rise, despite the clinician’s and
patient’s best efforts to calculate correct dosages. It is helpful
if elderly patients and their families know a correction factor
for these occasions so that they can adjust his or her insulin
dose accordingly.
If A1c levels are 7.0% or lower, the following formula
may be used to calculate the glucose correction factor (CF):
1700 ÷ TDD (in IU) = CF, where CF represents the degree
to which 1IU insulin is expected to lower the patient’s blood
glucose (in mg/dL) (Bode 2004). Therefore, if the patient is
on a TDD of 34 IU and taking a bolus analog insulin then
their CF would be 1700/34 meaning 1 unit of insulin will
bring their blood glucose down by about 50 points.
Therefore, if their blood glucose is 180mg/dL before a meal
you would add 1 additional unit as a correction factor to
their mealtime insulin to correct this high blood glucose.
It is important to caution elderly patients and their
families not to use this correction factor at bedtime because
rapid-acting insulin analogs are associated with peak
concentration levels and may result in nocturnal
hypoglycemia. If blood glucose levels are elevated before a
patient goes to bed, advise the patient and their family to
make a correction the following morning.
Summary: a delicate balance and
challenge – achieving the goal of
tighter glucose control in elderly
patients
Although many insulin-based regimens have been used
safely in elderly patients (Elgrabley et al 1991; Miles et al
1994), hypoglycemia is a concern and challenge for
obtaining tighter glycemic control, as mentioned. Known
risk factors for severe hypoglycemia in the elderly are recent
hospital discharge, advanced age, and polypharmacy or the
use of 5 or more prescribed medications (Shorr et al 1997).
Putative mechanisms for this include an age-associated
decrease in hepatic oxidative enzyme activity and
concomitant decline in renal function (Chelliah and Burge
2004). In addition, elderly patients, particularly those who
have had diabetes for many years, may lose epinephrine and
glucagons responses to hypoglycemia, leading to a lack of
awareness from loss of warning symptoms (Benbarka et al
1998).
Strategies to prevent this include educating the patient,
family, and close friends to recognize the signs and
symptoms of hypoglycemia, performing regular home blood
glucose monitoring, and practicing safe driving (Chelliah
and Burge 2004). It is important to advise patients to carry
a replacement glucose source in the pocket, purse, bedside
stand, and car. Additionally, many patients are unaware of
the blood glucose-lowering effect of alcohol and need to be
counseled about moderation and to ingest more
carbohydrates if they are going to imbibe.
Caring for elderly patients with diabetes necessitates
acknowledging the variability and complexity of this
population. As such, the target hemoglobin should always
be a reasonable goal that considers the patient’s status with
regard to clinical issues and physical, emotional and
cognitive functioning including consideration of life
expectancy (Blaum 2002; CHF 2003). While a goal of 7%
or lower may be appropriate for some older adults who are
healthy, such a target value for other older adults may be
inappropriate. Similarly, the establishment and prioritizing
of treatment goals needs to consider other common
syndromes in elderly patients with diabetes, such as
depression, injurious falls, and cognitive impairment. It is
important that clinicians continually reassess the patient’s
status and circumstances. It is worth informing patients and
families that self-management training and classes are
available and may be covered by insurance plans (for
example, annual training is covered under Medicare in the
US) (CHF 2003).
In summary, these new insulin analogs have created
another tool to enable the clinician to help their elderly
patients achieve consistent, well-defined glycemic control.
Although a strategy of basal-bolus insulin therapy using
these analogs lowers the incidence of hypoglycemia among
patients with diabetes, the clinician should remain ever
vigilant to this risk, especially in elderly patients. The
formulas presented serve as a guideline to help estimate a
patient’s insulin requirements, however it is important to
remember that all insulin titration must reflect the patient’s
unique characteristics to achieve ideal results and be
routinely monitored within the context of regular and
thorough geriatric assessments.Clinical Interventions in Aging 2006:1(2) 113
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